Form 4: Akebia Therapeutics SVP, Chief Medical Officer Steven Keith Burke Reports Sale of 27,000 Shares
SEC Form 4 Filing
Steven Keith Burke, SVP, Chief Medical Officer of Akebia Therapeutics, Inc., reported the sale of 27,000 shares of common stock at a price of $1.15 on August 25, 2023.
Summary
- On August 25, 2023, Steven Keith Burke, the SVP, Chief Medical Officer of Akebia Therapeutics, Inc. (AKBA), sold 27,000 shares of the company's common stock.
- The sale price was $1.15 per share.
- Following the transaction, Burke directly owns 668,840 shares of Akebia Therapeutics.
Sentiment
Score: 4
Explanation: The sentiment is neutral to slightly negative. While the document simply reports a transaction, insider selling can sometimes be perceived negatively by investors.
Negatives
- A company insider selling shares can sometimes be interpreted negatively by the market.
Risks
- Insider selling could potentially create negative market sentiment.
Industry Context
Insider trading activity is closely monitored by investors as it can provide insights into management's perspective on the company's valuation and future prospects. However, insider sales don't always indicate a negative outlook, as executives may sell shares for personal financial planning reasons.
Key Dates
| Date | Description |
|---|---|
| 08/25/2023 | Date of transaction: Steven Keith Burke sold 27,000 shares of Akebia Therapeutics common stock. |
| 05/09/2024 | Date of signature of Carolyn Rucci, attorney-in-fact for Steven K. Burke. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.